BI-1823911

N/A

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameBI-1823911
Drug Alias NameBI-1823911
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12C inhibitors
TargetsKRAS G12C
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International GmbhThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgThe University Of Texas MD Anderson Cancer CenterBoehringer Ingelheim International Gmbh
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A